In FL, GCB DLBCL, and BL, available data suggest that the BCR pathway is activated by antigen-independent mechanisms that involve interactions with mannose-binding lectins and/or deficiency of the negative regulator SHP1. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.